Camille Samuels

Camille Samuels

Camille (“Cami”) Samuels has spent the last 25 years financing and building start-up biopharma companies. She has been Partner at two premier venture capital firms: Versant Ventures and Venrock. She serves on the board of several biotechs (including Cavalry, Iris, Mahzi, and Unity), as well as on Duke University’s RTC Council, Harvard Business School’s Global Advisory Board, and the board of The Ehlers-Danlos Society. She previously served on the board of several public and/or acquired biotech companies, including Corvidia (sold to Novo), Kythera (sold to Allergan), Novacardia (sold to Merck), RegenXBio (ticker: RGNX), and Spirox (now part of Stryker). During her early career, Cami worked in corporate development at biotech companies, including Tularik (sold to Amgen), and she was a management consultant at LEK. Cami earned her bachelor’s degree in biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar.

Cami has hypermobile Ehlers-Danlos syndrome and its pentad sequelae. She is committed to leveraging her unique experience in drug development (and as a patient) to help those living with EDS and HSD and, more broadly, those suffering from rare disease